← 返回前沿论文

揭示 SYCP2 在宫颈病变中的表达及机制作用

英文原题:Unveiling the expression and mechanistic role of SYCP2 in cervical lesions.

PubMed 2025/11/03(内容时间) Discov Oncol Q3 · IF 2.8(JCR 2025)

研究概要

SYCP2成为HPV驱动宫颈癌变的关键生物标志物,对高级别病变具有诊断潜力,对转移风险具有预后价值。其在IL13RA2介导的信号传导中的调控作用以及与病毒应答通路的关联,提示其机制性参与肿瘤微环境重塑。这种双重的情境依赖性表达(在宫颈癌中上调而在其他恶性肿瘤中下调)凸显了组织特异性的致癌功能。这些发现使SYCP2成为HPV相关宫颈癌筛查和治疗策略的有前景的靶点。

研究思路结论见上方概要

持续HPV感染是宫颈癌发生的首要原因。尽管HPV检测作为筛查手段降低了宫颈癌发病率,但单独的HPV筛查无法区分持续性感染,因此需要新的分子标志物来识别宫颈上皮细胞中的有效HPV感染。

利用GEO数据库筛选与HPV阳性宫颈病变相关的基因,并通过ROC曲线分析评估SYCP2的诊断潜力。分析TCGA数据以探讨SYCP2与临床病理特征的相关性及预后意义。沉默SYCP2后的RNA-seq鉴定出差异表达基因,并通过GO/KEGG富集进行功能表征。在RNA/蛋白质水平验证下游效应因子IL13RA2。利用TISIDB数据库研究SYCP2与免疫学参数的相关性。

对四个GEO数据集的整合分析确定,与HPV阴性组织相比,SYCP2是HPV16阳性宫颈癌中一个关键上调基因。临床分析显示,SYCP2过表达与淋巴结转移和较差的无病生存期相关(HR (high) = 2.1,P = 0.0096)。ROC曲线显示其对宫颈病变具有诊断效能(CIN2+:AUC = 0.846(95%CI 0.777,0.915);CIN3+:AUC = 0.806(95%CI 0.731,0.881))。对SYCP2敲低细胞的RNA-seq鉴定出68个差异表达基因,GO/KEGG分析将SYCP2与病毒应答通路(例如甲型流感、麻疹)和细胞外基质重塑联系起来。可变剪接分析显示其在病毒致癌通路中富集。沉默SYCP2显著下调IL13RA2表达,并通过RT-PCR、Western blot和IL13 rescue实验得到验证。相关性分析显示,SYCP2表达水平与活化树突状细胞丰度(rho = - 0.347,P < 0.001)、调节性T细胞(rho = - 0.351,P < 0.001)、单核细胞(rho = -0.363,P < 0.001)、巨噬细胞(rho = - 0.327,P < 0.001)、髓源性抑制细胞(rho = - 0.313,P < 0.001)以及Gamma Delta T细胞(Tgd,rho = - 0.433,P < 0.001)的丰度呈统计学显著负相关。泛癌分析显示,SYCP2在宫颈鳞状细胞癌中上调,但在睾丸/甲状腺癌中下调。

展开英文摘要原文

BACKGROUND: Persistent HPV infection is the primary cause of cervical carcinogenesis. While HPV testing as a screening modality has reduced cervical cancer incidence, standalone HPV screening cannot distinguish persistent infections, necessitating novel molecular markers to identify effective HPV infection in cervical epithelial cells. METHODS: Genes associated with HPV-positive cervical lesions were screened using GEO databases, with SYCP2's diagnostic potential evaluated by ROC curve analysis. TCGA data were analyzed for SYCP2-clinicopathological correlations and prognostic significance. RNA-seq following SYCP2 silencing identified differentially expressed genes, with functional characterization via GO/KEGG enrichment. Downstream effector IL13RA2 was validated at RNA/protein levels. SYCP2-immunological parameter correlations were investigated using the TISIDB repository. RESULTS: Integrated analysis of four GEO datasets identified SYCP2 as a key upregulated gene in HPV16-positive cervical cancer compared to HPV-negative tissues. Clinical analyses revealed SYCP2 overexpression correlated with lymph node metastasis and worse disease-free survival (HR (high) = 2.1, P = 0.0096). ROC curves demonstrated diagnostic efficacy for cervical lesions (CIN2+: AUC = 0.846(95%C1 0.777, 0.915); CIN3+: AUC = 0.806(95%C1 0.731, 0.881)). RNA-seq of SYCP2-knockdown cells identified 68 differentially expressed genes, with GO/KEGG analyses linking SYCP2 to viral response pathways (e.g., influenza A, measles) and extracellular matrix remodeling. Alternative splicing analysis revealed enrichment in viral carcinogenesis pathways. SYCP2 silencing significantly downregulated IL13RA2 expression, validated via RT-PCR, Western blot, and IL13 rescue experiments. Correlation analyses revealed that SYCP2 expression levels showed statistically significant negative correlations with the abundance of Activated Dendritic Cells (rho = - 0.347, P < 0.001), Regulatory T cells (rho = - 0.351, P < 0.001), Monocytes (rho = -0.363, P < 0.001), Macrophages (rho = - 0.327, P < 0.001), Myeloid-Derived Suppressor Cells (rho = - 0.313, P < 0.001), and Gamma Delta T cells (Tgd, rho = - 0.433, P < 0.001). Pan-cancer analysis showed SYCP2 upregulation in cervical squamous carcinoma but downregulation in testicular/thyroid cancers. CONCLUSIONS: SYCP2 emerges as a critical biomarker for HPV-driven cervical carcinogenesis, with diagnostic potential for high-grade lesions and prognostic value for metastasis risk. Its regulatory role in IL13RA2-mediated signaling and association with viral response pathways suggest mechanistic involvement in tumor microenvironment remodeling. The dual context-dependent expression (upregulated in cervical cancer vs. downregulated in other malignancies) highlights tissue-specific oncogenic functions. These findings position SYCP2 as a promising target for HPV-associated cervical cancer screening and therapeutic strategies.

论文信息

作者
Zhu Y、Hou Z、Wang C、Hu H、Zhang Z、Yang X、Liu L、Ren C
第一作者单位
Department of Medical Genetics and Prenatal Diagnostics, The Third Affiliated Hospital of Zhengzhou University, No. 7, Front Kangfu Street, Zhengzhou, 450052, Henan Province, People's Republic of China.China
通讯作者单位
Department of Gynecology, The Third Affiliated Hospital of Zhengzhou University, No. 7, Front Kangfu Street, Zhengzhou, 450052, Henan Province, People's Republic of China. renchenchen1106@126.com.China
期刊
Discover oncology2025 Nov 3
原文标识
PubMed 41182523 · DOI 10.1007/s12672-025-03894-1